Globus Medical and Nevro Preliminary Full-Year 2024 Revenue Outlook: On January 8, 2025, Globus Medical announced preliminary 2024 net sales of $2.52 billion, an increase of 60.6% over prior year ...
Globus Medical said the purchase would increase its portfolio of musculoskeletal technologies, therefore enhancing its position in neuromodulation and chronic pain management. Nevro, with its ...
Globus Medical has a 12 month low of $49.33 and a 12 month high of $94.93. Globus Medical ( NYSE:GMED – Get Free Report ) last issued its quarterly earnings data on Tuesday, November 5th.
AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp ...
(RTTNews) - Globus Medical (GMED), a musculoskeletal solutions company, Thursday agreed to acquire Nevro Corp. (NVRO), a medical device company, in an all-cash transaction. Under the terms of the ...
Globus Medical (NYSE:GMED) said it has agreed to buy Nevro (NVRO) through an all-cash deal with an equity value of around $250M. Under the deal, Globus Medical (NYSE:GMED) will buy all of Nevro's ...
Globus Medical, Inc. (NYSE:GMED – Free Report) – Stock analysts at Roth Capital dropped their FY2024 earnings per share (EPS) estimates for shares of Globus Medical in a research note issued ...
Globus Medical will acquire Nevro for $250 million in cash, enhancing its musculoskeletal technology portfolio andglobal marketreach. Globus Medical and Nevro Corp. have agreed on an all-cash ...
Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Globus Medical (NYSE:GMED) in the last three months. In the table below, you'll find a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results